Credo Technology Group Bolsa (NASDAQ: CRDO)

Últimas noticias sobre Credo Technology Group (NASDAQ:CRDO) Bolsa

Credo Technology Group

Credo Technology Group Holding Ltd delivers high-speed solutions to break bandwidth barriers on every wired connection in the data infrastructure market. It provides secure, high-speed connectivity solutions that deliver improved power and cost efficiency as data rates and corresponding bandwidth requirements increase exponentially throughout the data infrastructure market. It has a geographic presence in Hong Kong, the United States, Mainland China, Taiwan, and the Rest of the World.

News

Price Target

Reiteration

Analyst Ratings

Tech

Trading Ideas

ALAB

ALGM

AVGO

CRDO

LSCC

MRVL

MTSI

NVDA

SLAB

SMTC

La demanda de IA impulsa a los semiconductores en 2024 y analistas predicen una recuperación para los segmentos análogos y automotrices.

Semiconductores en 2024: Impacto de la IA y Perspectivas para 2025

Credo Technology Group Holding Ltd - Ordinary Shares

Credo Technology Group Holding Ltd

Cerrado Gold Inc

Amid all the tariff drama and AI hype, the UK's equity market has been left for dead. That's exactly what makes it interesting right now.
While everyone else is chasing expensive U.S. tech stocks, the real value is hiding in plain sight—UK small caps. The setup here is simple: deep undervaluation, an improving macro backdrop, and a market that's so unloved it's primed for a sharp re-rating.
Smart investors who step in now could be handsomely rewarded.
Let me show you two of the best plays to make here right now.
Right now, UK small-cap stocks are trading at fire-sale prices. The FTSE SmallCap Index and AIM market are stuck at price-to-earnings (P/E) ratios that are downright ridiculous. The FTSE SmallCap Index is going for a forward P/E of around 10x—well below its long-term average of 14x. The price-to-book (P/B) ratio? Just 1.1x, compared to the historical 1.6x. This is a screaming deal, and history tells us that discounts this deep don't last forever. Sooner or later, the market wakes up.
The UK economy has been through the wringer, but there are signs of stabilization. The Bank of England is shifting gears, hinting at rate cuts in 2025. That's exactly the kind of catalyst small-cap stocks need. These companies are more sensitive to interest rates, and as borrowing costs fall, they'll get a tailwind. The last time we saw this kind of setup, small caps staged a powerful comeback. There's no reason to think history won't repeat itself.
For years, Brexit and economic worries battered the British pound, making UK stocks less attractive to global investors. But that's changing. The currency has stabilized, and as confidence returns, so will foreign capital. The best part? With UK stocks trading at multi-year discounts, international money managers will have no choice but to start paying attention. And when they do, prices will move up fast.
Smart money knows a deal when they see one. In 2024 alone, over £50 billion worth of UK-listed companies were snapped up by private equity and institutional investors. And the trend isn't slowing down—some analysts expect that up to a third of smaller companies on the AIM market could be takeover targets in 2025. If private equity sharks are circling, it's a sure sign of value. If you buy in before the deals accelerate, you could be looking at serious upside.
Right now, investor sentiment toward UK stocks is in the gutter. That's the best time to buy. Every cycle has a turning point, and we may be at one now. As global capital starts looking for value again, UK small caps—beaten down and ignored—will be the perfect hunting ground. Those who get in early will be rewarded when the herd finally catches on.
This isn't a flashy, momentum-driven trade—it's a classic value investor's dream. UK small-cap stocks are dirt cheap, the macro picture is shifting in their favor, and the market is asleep at the wheel. When conditions like this appear, the play is simple: step in, buy quality businesses at a discount, and let time do the heavy lifting. If history is any guide, those who buy now will be glad they did when the market finally wakes up.
One stock that absolutely deserves a closer look is Navigator Holdings Ltd (NVGS). This company operates a fleet of liquefied gas carriers, a sector benefiting from rising global energy trade. Despite strong fundamentals, Navigator is trading at a discount, with a price-to-earnings ratio below 10x and a price-to-book ratio under 1.2x. Demand for liquefied gases is expected to remain robust, and the company's long-term contracts provide earnings visibility. With a strong balance sheet and increasing free cash flow, Navigator Holdings is an undervalued asset in a sector poised for continued growth. Investors looking for a well-priced, high-potential play should be taking a serious position in NVGS before the broader market catches on.
Another stock that deserves investor attention is Gambling.com Group (GAMB). This online gaming and betting affiliate platform is capitalizing on the expansion of regulated online gambling markets worldwide. With strong profitability, high margins, and impressive revenue growth, GAMB is proving its ability to generate consistent earnings. The company's scalable model and disciplined cost management make it a high-quality asset in an industry with strong tailwinds. As online gambling continues to gain traction, Gambling.com Group is positioned for long-term success, making it a solid buy for investors looking for exposure to a lucrative and expanding market.
UK small-cap stocks are an absolute steal right now. We have deep discounts, improving economic conditions, and a shift in investor sentiment right around the corner. The last time we saw these kinds of valuations, the returns were explosive for those who got in early.&nbsp;
The smart money is already moving, and if you are serious about compounding capital, this is an opportunity you don&#8217;t want to miss.&nbsp;
The time to act is now—before the rest of the world wakes up to what's happening.
<a href="https://www.benzinga.com/premium/ideas/benzinga-edge/?el=ResearchDaily&amp;he={{email}}&amp;adt_ei={{email}}&amp;utm_adType=SponsorAd&amp;utm_ad=RD0213&amp;utm_campaign=wallstreetadvantage">The Only Membership With a Positive ROI</a>
Gain your competitive Edge in markets with a steady stream of new stock ideas, proprietary data, and expert insights. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge/?el=ResearchDaily&amp;he={{email}}&amp;adt_ei={{email}}&amp;utm_adType=SponsorAd&amp;utm_ad=RD0213&amp;utm_campaign=wallstreetadvantage">Get started right here.</a>
Image via Shutterstock

Opinion

Buy These 2 Great Stocks at Fire-Sale Prices While You Still Can

Coupang's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPNG#NYSE">CPNG</a>) short percent of float has fallen 4.08% since its last report. The company recently reported that it has 14.14 million shares sold short, which is 1.41% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.12 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Coupang Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739216723_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Coupang has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Coupang's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Coupang's peer group average for short interest as a percentage of float is 9.94%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

CPNG

Peering Into Coupang's Recent Short Interest

Cushman &amp; Wakefield's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CWK#NYSE">CWK</a>) short percent of float has risen 3.87% since its last report. The company recently reported that it has 14.40 million shares sold short, which is 7.24% of all regular shares that are available for trading. Based on its trading volume, it would take traders 9.35 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Cushman &amp; Wakefield Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739216718_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Cushman &amp; Wakefield has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Cushman &amp; Wakefield's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Cushman &amp; Wakefield's peer group average for short interest as a percentage of float is 5.99%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Looking Into Cushman & Wakefield's Recent Short Interest

ASGN's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASGN#NYSE">ASGN</a>) short percent of float has risen 4.76% since its last report. The company recently reported that it has 2.06 million shares sold short, which is 6.38% of all regular shares that are available for trading. Based on its trading volume, it would take traders 6.67 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>ASGN Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739216713_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for ASGN has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing ASGN's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, ASGN's peer group average for short interest as a percentage of float is 3.57%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

ASGN

Looking Into ASGN's Recent Short Interest

Mounting global trade tensions are leading to sharp market fluctuations as investors are scrambling for ways <a href="https://www.benzinga.com/topic/trade-war">to protect their portfolios</a>. 
The U.S. has imposed tariffs on major trade partners, including Mexico, Canada, and China, leading to economic uncertainty. 
As a result, <a href="https://www.benzinga.com/etfs">ETFs have emerged</a> as a safe option for those looking to hedge against volatility while maintaining diversified exposure to various asset classes.
Also Read: <a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/25/02/43598271/5-etfs-that-beat-market-turmoil-with-gains-last-week">5 ETFs That Beat Market Turmoil With Gains Last Week</a>
<ul>
<li>SPDR Gold Shares (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLD#NYSE">GLD</a>): Gold has long been a preferred asset during market turmoil. The SPDR Gold Shares ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLD#NYSE">GLD</a>) provides direct exposure to gold, which often rises with the rise of uncertainties, making it a strong hedge against economic instability. The ETF price has grown 42.88% in the past year.</li>
</ul>
<ul>
<li>Invesco S&amp;P 500 Low Volatility ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPLV#NYSE">SPLV</a>): For those who want equity exposure with reduced volatility, the Invesco S&amp;P 500 Low Volatility ETF selects stocks with historically lower price fluctuations, aiming for steadier performance. The fund boasts a 1-year price return of 13.72%.</li>
</ul>
<ul>
<li>Vanguard Consumer Staples ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VDC#NYSE">VDC</a>): Consumer staples remain resilient in uncertain economic conditions, as everyday essentials will continue to be in demand. The Vanguard Consumer Staples ETF includes key players like Procter &amp; Gamble (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PG#NYSE">PG</a>) and Coca-Cola (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KO#NYSE">KO</a>), offering a defensive strategy against economic downturns.</li>
</ul>
<h3 class="wp-block-heading">Market Turbulence from the Trade War</h3>
The recent imposition of tariffs by the U.S. on major trade partners—Mexico, Canada, and China—has injected significant uncertainty into the markets. With 25% tariffs on Canadian and Mexican imports and a 10% levy on Chinese goods, equities initially reacted negatively. Although a temporary pause on tariffs for Mexico and Canada provided a brief market recovery, it is widely believed that Trump will go ahead with the policies one day or the other.
In another step in his trade policy overhaul, Reuters reported that on Feb. 9, Trump said he will introduce fresh <a href="https://www.benzinga.com/government/regulations/25/02/43592144/us-steel-aluminum-stocks-rally-as-trump-revives-25-tariff-plan">25% tariffs </a>on all steel and aluminum imports into the U.S. These tariffs will add to the existing metals duties.
Strong retaliatory <a href="https://www.benzinga.com/news/global/25/02/43600852/china-sets-sights-on-us-tech-companies-as-trade-tensions-rise">tariffs from China</a>, and sanction plans on U.S. goods by Canada and Mexico are adding to the nail-biting situation.
Additionally, with the Fed keeping interest rates unchanged in their recent meeting led investors to lower their expectations for lower rates, throwing the market into more uncertainty.
According to the CME <a href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html">FedWatch </a>Tool, the Fed has a 91.5% probability of keeping the rates unchanged at 4.25-4.5% in March, while there&#8217;s an 8.1% chance that the Fed cut the rate to 4%-4.25% in its March meeting.
While trade conflicts can cause market swings, investors can mitigate risks by allocating capital to ETFs that focus on keeping investors&#8217; money safe. Whether through gold, Treasuries or defensive equities, these funds offer more opportunities to diversification and manage risks as global trade policies evolve.
Read Next:<a href="https://www.benzinga.com/etfs/new-etfs/25/02/43599972/new-bitcoin-etf-limits-losses-to-20-offers-risk-controlled-exposure"> </a>
<ul>
<li><a href="https://www.benzinga.com/etfs/new-etfs/25/02/43599972/new-bitcoin-etf-limits-losses-to-20-offers-risk-controlled-exposure">New Bitcoin ETF Limits Losses To 20%, Offers Risk-Controlled Exposure</a></li>
</ul>
Photo: Shutterstock

Broad U.S. Equity ETFs

ETFs

EEMV

GOVT

PowerShares S&P 500 Low Volatility Portfolio

SPLV

As Trade War Heats Up, These ETFs Offer A Safe Harbor For Investors

GameStop Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GME#NYSE">GME</a>) shares are trading higher Monday after CEO Ryan Cohen posted a picture with MicroStrategy Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) <a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43596456/strategy-acquires-7633-bitcoin-for-742-4-million-boosts-holdings-to-478740-btc">Michael Saylor</a>.
What Happened: Cohen posted a picture with Saylor on <a href="https://x.com/ryancohen/status/1888098643732811864">X</a> over the weekend, which appears to have sparked speculation that the company could be leaning further into Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>).
MicroStrategy, which recently <a href="https://www.benzinga.com/news/earnings/25/02/43511849/strategy-q4-earnings-bitcoin-treasury-company-spends-20-5b-on-btc-shares-inch-higher-despite-revenue-miss">rebranded to &#8220;Strategy,&#8221;</a> is the largest corporate holder of Bitcoin. GameStop previously made a push into the crypto space with the launch of wallets that let users manage crypto and non-fungible tokens (NFTs) and also provided access to GameStop's NFT marketplace. However, the company closed down the offering in 2023 due to <a href="https://www.benzinga.com/markets/cryptocurrency/23/08/33511904/gamestop-cites-regulatory-uncertainty-drops-ios-chrome-extension-crypto-wallet-support">&#8220;regulatory uncertainty.&#8221;</a>
GameStop reported third-quarter financial results in December. The company included a note in the filing showing that it was <a href="https://www.benzinga.com/analyst-ratings/analyst-color/23/12/36142175/meme-king-ryan-cohen-now-able-to-trade-stocks-with-gamestop-funds">freeing up Cohen to bet on stocks</a> in order to improve the company&#8217;s financial standing. 
&#8220;We have traditionally invested our excess cash in investment grade short-term fixed income securities, which consist of U.S. government and agency securities and time deposits,&#8221; the company said.
&#8220;On December 5, 2023, the Board of Directors approved a new investment policy that permits the Company to invest in equity securities, among other investments.&#8221;
Check This Out: <a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43596456/strategy-acquires-7633-bitcoin-for-742-4-million-boosts-holdings-to-478740-btc">Strategy Acquires 7,633 Bitcoin For $742.4 Million, Boosts Holdings To 478,740 BTC</a>
GameStop said in the filing that Cohen would lead the investment activity for GameStop in public and private markets. Cohen is the company&#8217;s largest shareholder with approximately an 8.2% stake. 
The photo also follows a regulatory filing from the end of January showing that Cohen transferred ownership of more than 36.8 million GameStop shares from RC Ventures LLC to his personal name. The move <a href="https://www.benzinga.com/general/gaming/25/01/43342224/ryan-cohen-moves-gamestop-shares-to-personal-name-sparking-speculation-on-next-steps">sparked speculation</a> on social media that Cohen could be considering a merger or acquisition for GameStop, among other possibilities. 
GameStop has been one of the most popular retail stocks in recent years ever since the historic 2021 meme stock craze that saw GameStop and other heavily shorted names squeeze higher. Meme stock trader Keith Gill, also known as <a href="https://www.benzinga.com/topic/roaring-kitty">"Roaring Kitty,&#8221;</a> has continued to influence GameStop price action with cryptic posts on X. 
Gill&#8217;s latest post on Jan. 22 featured a dog hanging out on a sidewalk outside of a pizza shop. The song "I Will Wait For You," sung by Connie Francis, plays throughout as the dog appears to be waiting for something. GameStop shares briefly popped on the post. 
GME Price Action: <a href="http://benzinga.com/quote/gme">GameStop shares</a> are up approximately 83% over a one-year period. The stock was up 7.86% at $26.67 at the time of publication Monday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: Shutterstock.

Movers

$BTC

MSTR

GameStop Stock Is Surging Monday: What's Going On?

<a href="https://www.eqs-news.com/news/ad-hoc/merck-kgaa-merck-kgaa-confirms-discussions-with-springworks-therapeutics-inc-on-potential-acquisition/347bfb1b-819d-4d8f-8a3e-4fd6092643e8" title="https://www.eqs-news.com/news/ad-hoc/merck-kgaa-merck-kgaa-confirms-discussions-with-springworks-therapeutics-inc-on-potential-acquisition/347bfb1b-819d-4d8f-8a3e-4fd6092643e8">https://www.eqs-news.com/news/ad-hoc/merck-kgaa-merck-kgaa-confirms-discussions-with-springworks-therapeutics-inc-on-potential-acquisition/347bfb1b-819d-4d8f-8a3e-4fd6092643e8</a>

Merck KGAA Confirms Discussions With Springworks Therapeutics On Potential Acquisition

<a href="https://www.benzinga.com/real-estate/24/12/42440855/barstool-sports-founder-dave-portnoys-shocking-admission-his-former-partner-has-full-access-to-his-150m-cash-assets-and-65m-property-portfolio">Barstool Sports founder Dave Portnoy</a> is doubling down on his commitment to the meme coin Stool Prisondente (CRYPTO: JAILSTOOL), even as traders question its future.
What Happened: Portnoy, who initially invested hundreds of thousands of dollars in the token, insists he remains committed, despite the coin's struggles.
In an X post Monday evening, he <a href="https://x.com/stoolpresidente/status/1889015371400958106?s=19">emphasized </a>his dedication, saying, &#8220;The fact I'm still putting my own money into #Jailstool cause I don't want people losing money shows that my heart is too big for this stupid space. I need a blacker heart. Rise #Jailstool rise.&#8221;
His statement comes after scrutiny from crypto traders, some of whom argue that Jailstool's decline has hurt retail investors.
However, Portnoy maintains he's stayed true to his word, refusing to take early profits and continuing to support the project.
"I put 100's of thousands of my own money into #Jailstool and promised up to 1 million more as it grew," Portnoy <a href="https://x.com/stoolpresidente/status/1888972298004135943">wrote</a> in another post. "I coulda cashed out for 6 million. I didn't. But I'm not just gonna promote forever for free while sharks eat Minos. I've done exactly what I promised to do like I always do. 100% transparent."
The price of Jailstool crashed around 82% on Monday evening European time to 2 cents, after making a high of 21 cents a day earlier, according to CoinGecko <a href="https://www.coingecko.com/en/coins/stool-prisondente">data</a>.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43596456/strategy-acquires-7633-bitcoin-for-742-4-million-boosts-holdings-to-478740-btc">Strategy Acquires 7,633 Bitcoin For $742.4 Million, Boosts Holdings To 478,740 BTC</a>
Why It Matters: Portnoy's approach has divided the crypto community.
Some traders see his investment as a genuine attempt to back the community, while others remain skeptical about his long-term credibility in the space.
Crypto analyst Stats <a href="https://x.com/punk9059/status/1888975984751493228">said</a> that Jailstool has nearly returned to its pre-promotion price, raising concerns about the effectiveness of Portnoy's marketing.
"His marketing plays didn&#8217;t work out. People lost real money (which is 100% their own fault). But I think his credibility in this space is pretty ruined," he wrote.
Others, like Kaleo, speculated that Portnoy might keep investing in Jailstool to try and stabilize its price. 
"With how much he&#8217;s talked about &#8216;not even thinking of selling this until it hits &gt;$500M,' feels like there&#8217;s a solid chance he lets his pride get the best of him," Kaleo tweeted, predicting that if Portnoy loses money, he'll turn against meme coins altogether.
Despite the backlash, Portnoy remains a major investor in Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) and XRP (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>), recently revealing that he <a href="https://www.benzinga.com/24/12/42602503/dave-portnoy-says-he-owns-15-million-bitcoin-13-million-xrp-bet-it-and-set-it-not-trading">holds $1.5 million in Bitcoin and $1.3 million in XRP</a>.
His Bitcoin investment followed a conversation with Strategy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) chairman Michael Saylor, who convinced him of Bitcoin's long-term value. 
During their interview, Saylor explained Bitcoin through sports analogies, saying, "Satoshi created a game that is rigged in favor of the individual… Bitcoin is that game."
Portnoy, once a skeptic, has since embraced Bitcoin, stating, "I&#8217;m gonna bet it and set it, not trading." 
However, his latest Jailstool debacle has reignited doubts about his role in crypto, with many traders now questioning whether he should be <a href="https://www.benzinga.com/24/12/42602503/dave-portnoy-says-he-owns-15-million-bitcoin-13-million-xrp-bet-it-and-set-it-not-trading">taken seriously in the space.</a>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43591727/coinbase-ceo-brian-armstrong-says-bitcoin-adoption-to-reach-billions-by-2030">Coinbase CEO Brian Armstrong Says Bitcoin Adoption To Reach &#8216;Billions&#8217; By 2030</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$XRP

Dave Portnoy Holds Millions In Bitcoin And XRP, But Here's Why He Concluded His Heart Is 'Too Big For This Space'

Deep-pocketed investors have adopted a bullish approach towards Nebius Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIS#NASDAQ">NBIS</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in NBIS usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 53 extraordinary options activities for Nebius Group. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 49% leaning bullish and 33% bearish. Among these notable options, 10 are puts, totaling $607,382, and 43 are calls, amounting to $6,593,370.
<h3>Expected Price Movements</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $10.0 to $60.0 for Nebius Group over the last 3 months. 
<h3>Volume &amp; Open Interest Trends</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Nebius Group's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Nebius Group's significant trades, within a strike price range of $10.0 to $60.0, over the past month.
<h3>Nebius Group Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739215829_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>NBIS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$12.2</td>
<td>$11.0</td>
<td>$11.9</td>
<td>$45.00</td>
<td>$4.1M</td>
<td>884</td>
<td>3.5K</td>
</tr>
<tr>
<td>NBIS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$6.3</td>
<td>$6.1</td>
<td>$6.3</td>
<td>$40.00</td>
<td>$126.0K</td>
<td>3.7K</td>
<td>897</td>
</tr>
<tr>
<td>NBIS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$7.2</td>
<td>$6.9</td>
<td>$7.2</td>
<td>$35.00</td>
<td>$111.6K</td>
<td>9.1K</td>
<td>672</td>
</tr>
<tr>
<td>NBIS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$4.3</td>
<td>$4.1</td>
<td>$4.2</td>
<td>$40.00</td>
<td>$105.0K</td>
<td>12.2K</td>
<td>1.4K</td>
</tr>
<tr>
<td>NBIS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$4.2</td>
<td>$4.0</td>
<td>$4.0</td>
<td>$45.00</td>
<td>$100.0K</td>
<td>3.0K</td>
<td>296</td>
</tr>
</tbody>
</table>

<h3>About Nebius Group</h3>
Nebius Group NV is a tech company. It is a European provider of infrastructure and services to AI builders globally. The group builds full-stack infrastructure to service the growth of the AI industry, including the scale of GPU clusters, cloud platforms, tools, and services for developers. It has R&amp;D hubs across Europe, North America and Israel.
<h3>Nebius Group's Current Market Status</h3>
<ul>
<li>Currently trading with a volume of 10,536,797, the NBIS's price is up by 7.8%, now at $41.1. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 11 days.</li>
</ul>
<h3>Expert Opinions on Nebius Group</h3>
A total of 2 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $51.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from BWS Financial keeps a Buy rating on Nebius Group with a target price of $51. 
&#x2A; Reflecting concerns, an analyst from BWS Financial lowers its rating to Buy with a new price target of $51.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Nebius Group, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Options

Markets

NBIS

Nebius Group Unusual Options Activity For February 10

Investors with a lot of money to spend have taken a bullish stance on AstraZeneca (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>).
And retail traders should know.
We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with AZN, it often means somebody knows something is about to happen.
Today, Benzinga's options scanner spotted 9 options trades for AstraZeneca.
This isn't normal.
The overall sentiment of these big-money traders is split between 55% bullish and 44%, bearish.
Out of all of the options we uncovered, there was 1 put, for a total amount of $33,835, and 8, calls, for a total amount of $3,881,635.
<h3>Expected Price Movements</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $65.0 and $77.5 for AstraZeneca, spanning the last three months.
<h3>Analyzing Volume &amp; Open Interest</h3>
In today's trading context, the average open interest for options of AstraZeneca stands at 1003.75, with a total volume reaching 7,809.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in AstraZeneca, situated within the strike price corridor from $65.0 to $77.5, throughout the last 30 days.
<h3>AstraZeneca Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739215824_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>AZN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$5.9</td>
<td>$5.55</td>
<td>$5.8</td>
<td>$77.50</td>
<td>$1.9M</td>
<td>3.1K</td>
<td>0</td>
</tr>
<tr>
<td>AZN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$3.3</td>
<td>$3.15</td>
<td>$3.2</td>
<td>$75.00</td>
<td>$1.0M</td>
<td>2.4K</td>
<td>3.5K</td>
</tr>
<tr>
<td>AZN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$2.34</td>
<td>$2.0</td>
<td>$2.3</td>
<td>$77.50</td>
<td>$689.9K</td>
<td>535</td>
<td>3.0K</td>
</tr>
<tr>
<td>AZN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$8.2</td>
<td>$8.15</td>
<td>$8.15</td>
<td>$65.00</td>
<td>$39.1K</td>
<td>920</td>
<td>368</td>
</tr>
<tr>
<td>AZN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$8.0</td>
<td>$7.8</td>
<td>$8.0</td>
<td>$65.00</td>
<td>$38.3K</td>
<td>920</td>
<td>740</td>
</tr>
</tbody>
</table>

<h3>About AstraZeneca</h3>
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, immunology and rare diseases. The majority of sales come from international markets with the United States representing close to one third of its sales.
Having examined the options trading patterns of AstraZeneca, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Where Is AstraZeneca Standing Right Now?</h3>
<ul>
<li>Trading volume stands at 4,149,033, with AZN's price up by 0.87%, positioned at $72.61.</li>
<li>RSI indicators show the stock to be may be overbought.</li>
<li>Earnings announcement expected in 73 days.</li>
</ul>
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for AstraZeneca, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Unpacking the Latest Options Trading Trends in AstraZeneca

High-rolling investors have positioned themselves bullish on GEO Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEO#NYSE">GEO</a>), and it's important for retail traders to take note. 
\This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in GEO often signals that someone has privileged information.
Today, Benzinga's options scanner spotted 15 options trades for GEO Group. This is not a typical pattern.
The sentiment among these major traders is split, with 46% bullish and 26% bearish. Among all the options we identified, there was one put, amounting to $28,200, and 14 calls, totaling $860,227.
<h3>What's The Price Target?</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $21.0 to $35.0 for GEO Group during the past quarter. 
<h3>Volume &amp; Open Interest Trends</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for GEO Group's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of GEO Group's whale trades within a strike price range from $21.0 to $35.0 in the last 30 days. 
<h3>GEO Group Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739215819_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>GEO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$3.2</td>
<td>$3.1</td>
<td>$3.2</td>
<td>$29.00</td>
<td>$206.7K</td>
<td>5.4K</td>
<td>1.0K</td>
</tr>
<tr>
<td>GEO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$3.6</td>
<td>$3.3</td>
<td>$3.6</td>
<td>$29.00</td>
<td>$122.4K</td>
<td>5.4K</td>
<td>1.5K</td>
</tr>
<tr>
<td>GEO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$9.9</td>
<td>$9.8</td>
<td>$9.9</td>
<td>$22.00</td>
<td>$59.4K</td>
<td>7.7K</td>
<td>584</td>
</tr>
<tr>
<td>GEO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$3.2</td>
<td>$2.95</td>
<td>$3.2</td>
<td>$29.00</td>
<td>$58.5K</td>
<td>5.4K</td>
<td>212</td>
</tr>
<tr>
<td>GEO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$3.6</td>
<td>$3.5</td>
<td>$3.5</td>
<td>$29.00</td>
<td>$56.0K</td>
<td>5.4K</td>
<td>1.2K</td>
</tr>
</tbody>
</table>

<h3>About GEO Group</h3>
The GEO Group Inc specializes in detention facilities and community reentry centers. It operates in four segments: U.S. Secure Services, which mainly encompasses U.S.-based secure services business; Electronic Monitoring and Supervision Services, which conducts its services in the United States, represents services provided to adults for monitoring services and evidence-based supervision and treatment programs for community-based parolees, probationers, and pretrial defendants; Reentry Services conducts its services in the United States represents services provided to adults for residential and non-residential treatment, educational and community-based programs, pre-release and half-way house programs; and International Services.
After a thorough review of the options trading surrounding GEO Group, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Present Market Standing of GEO Group</h3>
<ul>
<li>Currently trading with a volume of 1,095,181, the GEO's price is up by 0.45%, now at $27.05. </li>
<li>RSI readings suggest the stock is currently may be approaching oversold.</li>
<li>Anticipated earnings release is in 17 days.</li>
</ul>
<h3>What The Experts Say On GEO Group</h3>
Over the past month, 1 industry analysts have shared their insights on this stock, proposing an average target price of $55.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from Jones Trading keeps a Buy rating on GEO Group with a target price of $55. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for GEO Group, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Smart Money Is Betting Big In GEO Options

Coca-Cola Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KO#NYSE">KO</a>) will be reporting its fourth-quarter earnings on Tuesday. Wall Street expects 52 cents in EPS and $10.68 billion in revenues as the company reports<a href="https://www.benzinga.com/calendars/earnings?tickers=KO" target="_blank" rel="noreferrer noopener"> before market hours</a>.
The stock is up 7.45% over the past year, 3.74% year-to-date.
Let&#8217;s look at what the charts indicate for Coca-Cola stock and how the stock currently maps against Wall Street estimates.
Read Also: <a href="https://www.benzinga.com/news/earnings/25/02/43591420/how-to-earn-500-a-month-from-coca-cola-stock-ahead-of-q4-earnings">How To Earn $500 A Month From Coca-Cola Stock Ahead Of Q4 Earnings</a>
<h2 class="wp-block-heading">KO Stock Strongly Bullish Ahead Of Q4 Earnings</h2>
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent021025&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="631" height="486" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/10130007/Screenshot-2025-02-10-at-11.24.24-PM.png" alt="" class="wp-image-775053" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/10130007/Screenshot-2025-02-10-at-11.24.24-PM.png 631w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/10130007/Screenshot-2025-02-10-at-11.24.24-PM-300x231.png 300w" sizes="(max-width: 631px) 100vw, 631px" /></a></figure>
<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent021025&amp;t=be2bearmibe3na1">Chart created using Benzinga Pro</a>
Coca-Cola stock is exhibiting a strongly bullish trend, with its share price trading above the eight-day, 20-day and 50-day simple moving averages. This sustained buying pressure indicates positive momentum, suggesting the potential for continued upside.
The stock's strength is further reinforced by its Moving Average Convergence Divergence (MACD) indicator at 0.33, signaling bullish momentum.
Additionally, KO stock's Relative Strength Index (RSI) stands at 58.00, placing it in neutral territory but trending toward overbought levels. This suggests that while the stock remains in an uptrend, investors should monitor for potential consolidation or a cooling-off period. 
If buying pressure persists, Coca-Cola stock could continue its bullish trajectory, making it an attractive option for momentum-focused investors.
<h2 class="wp-block-heading">Coca-Cola Analysts See 11% Upside</h2>
Ratings &amp; Consensus Estimates:<a href="https://www.benzinga.com/quote/KO/analyst-ratings" target="_blank" rel="noreferrer noopener"> The consensus analyst rating</a> on Coca-Cola stock stands at a Buy currently with a price target of $71.30. The latest analyst ratings from RBC Capital, Jefferies and JPMorgan imply an 11.3% upside for KO stock, with an average price target of $71.33.
Stock Price Action: Coca-Cola stock was trading at $64 at the time of publication.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/02/43494592/jpmorgan-picks-winners-losers-after-deepseek-debut-how-alphabet-amazon-intel-and-oracle-rank">JPMorgan Picks Winners, Losers After DeepSeek Debut: How Alphabet, Amazon, Intel And Oracle Rank</a></li>
</ul>
Image: Shutterstock

Technicals

Previews

Coca-Cola Stock Is Bubbling Higher: Can Q4 Earnings Keep The Fizz Going?

A new <a href="https://www.researchsquare.com/article/rs-5921911/v1">study</a> suggests that cannabinoids like THC, CBD and CBN may help regulate blood sugar levels, potentially outperforming some existing diabetes drugs. It should be noted, however, that since this study is not peer-reviewed and remains purely theoretical, any potential applications remain speculative at this stage. The research requires further validation before any clinical applications can be considered.
<h3 class="wp-block-heading">Study Highlights Multi-Target Potential Of Cannabinoids</h3>
Researchers from the University of the Free State and the University of Yaoundé 1 conducted an in silico molecular docking study to assess the interactions between six cannabinoids and four key enzymes involved in glucose metabolism: dipeptidyl peptidase-4 (DPP-4), α-glucosidase, α-amylase and invertase. These enzymes play essential roles in breaking down carbohydrates and regulating post-meal glucose spikes, making them primary targets for type 2 diabetes treatments.
According to the study, cannabinoids showed stronger binding affinities to these enzymes compared to some standard diabetes drugs, with the exception of DPP-4 inhibitors. THC and CBN demonstrated particularly strong interactions, suggesting they might modulate multiple metabolic pathways simultaneously.
The study suggests that cannabinoids exhibit multi-target binding to key type 2 diabetes drug targets, indicating their potential for further investigation as anti-diabetic agents.
<h3 class="wp-block-heading">Why This Matters</h3>
With <a href="https://diabetesatlas.org/atlas/tenth-edition/">537 million</a> people worldwide living with diabetes, the demand for effective and safer treatment options continues to grow. While traditional diabetes medications focus on single pathways, cannabinoids may offer a multi-target approach, potentially improving glucose control while reducing side effects.
Previous studies have hinted at cannabis compounds&#8217; metabolic effects, with research showing that <a href="https://www.frontiersin.org/journals/nutrition/articles/10.3389/fnut.2023.1150189/full">CBD</a> may reduce insulin resistance and inflammation, while <a href="https://pubmed.ncbi.nlm.nih.gov/33526143/">THCV</a> has been linked to appetite suppression and improved metabolic function. However, the exact mechanisms remain unclear.
<h3 class="wp-block-heading">The Caveats: What This Study Doesn&#8217;t Prove</h3>
Despite the promising results, this study remains theoretical. It relies solely on computer simulations, meaning no clinical trials or real-world testing have been conducted to confirm the effects of cannabinoids on blood sugar regulation.
Additionally, while the study suggests that cannabinoids bind well to key enzymes, binding affinity alone does not guarantee therapeutic efficacy. Factors such as bioavailability, metabolism and dosage need to be studied in laboratory and human trials before any conclusions can be drawn.
It's also important to note that the research has not yet been peer-reviewed, meaning it has not undergone rigorous scientific scrutiny. Until further studies validate these findings, cannabinoids should not be considered a proven treatment for diabetes. While these findings are interesting, they do not constitute medical proof. Without clinical validation, there is no certainty that cannabinoids will have the same effects in living organisms as seen in computer models.
<h3 class="wp-block-heading">What's Next?</h3>
For cannabinoids to be seriously considered in diabetes management, animal and human trials must confirm their efficacy and safety. Future research should also explore how different cannabinoids interact with each other and whether non-psychoactive compounds like CBG and THCV could offer metabolic benefits without the high association with THC.
While cannabis-based medicines are already being explored for conditions like epilepsy and chronic pain, their potential in diabetes remains largely untapped. If future studies support these findings, we may see the development of novel cannabinoid-based therapies targeting blood sugar control.
For now, this study is a stepping stone, not a breakthrough—a signal that further investigation is warranted, but not a replacement for existing treatments.
Lead image via Shutterstock

Cannabis

Health Care

Could Cannabis Compounds Outperform Diabetes Drugs? Early Findings Show Potential, But More Research Is Needed

U.S. stocks traded higher toward the end of trading, with the Dow Jones index jumping more than 150 points on Monday.
The Dow traded up 0.40% to 44,482.54 while the NASDAQ gained 1.16% to 19,750.22. The S&amp;P 500 also rose, gaining, 0.75% to 6,071.29.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/25/02/43559194/jim-cramer-likes-this-utilities-stock-i-think-youve-got-a-good-one">Jim Cramer Likes This Utilities Stock: &#8216;I Think You&#8217;ve Got A Good One&#8217;</a>
Leading and Lagging Sectors Energy shares surged by 2% on Monday.
In trading on Monday, financial shares fell by 0.6%.
Top Headline
U.S. consumer inflation expectations for the year ahead came in steady for a third straight month at 3% in January.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>SpringWorks Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWTX#NASDAQ">SWTX</a>) shares shot up 36% to $54.85 after announcing Merck KGaA is in advanced discussions to acquire the company.</li>
<li>Shares of Biodexa Pharmaceuticals Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDRX#NASDAQ">BDRX</a>)got a boost, surging 42% to $5.78 after the company announced it received FDA fast-track designation for eRapa.</li>
<li>monday.com Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNDY#NASDAQ">MNDY</a>) shares were also up, gaining 28% to $331.46 after the company reported better-than-expected fourth-quarter financial results and first-quarter revenue outlook.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Pliant Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRX#NASDAQ">PLRX</a>) shares dropped 59% to $3.1893. On Friday, Pliant Therapeutics announced it has voluntarily paused enrollment and dosing in the ongoing BEACON-IPF Phase 2b trial of bexotegrast in patients with idiopathic pulmonary fibrosis (IPF), a chronic lung disease that causes scarring and stiffening of the lung tissue.</li>
<li>Shares of Manhattan Associates, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MANH#NASDAQ">MANH</a>) were down 11% to $179.24. The company announced its president and CEO Eddie Capel will retire.</li>
<li>Semtech Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMTC#NASDAQ">SMTC</a>) was down, falling 31% to $37.60 after Needham cut its price target on the stock from $74 to $54.</li>
</ul>
Commodities In commodity news, oil traded up 1.7% to $72.22 while gold traded up 1.7% at $2,935.20.
Silver traded up 0.2% to $32.515 on Monday, while copper rose 2.6% to $4.7060.
Euro zone
European shares were higher today. The eurozone's STOXX 600 gained 0.58%, Germany's DAX 40 rose 0.57% and France's CAC 40 rose 0.52%. Spain's IBEX 35 Index rose 0.16%, while London's FTSE 100 rose 0.77%.
Asia Pacific Markets
Asian markets closed mostly higher on Monday, with Japan's Nikkei 225 gaining 0.04%, China's Shanghai Composite Index climbing 0.56%, Hong Kong's Hang Seng Index gaining 1.84% and India's BSE Sensex falling 0.70%.
Economics
U.S. consumer inflation expectations for the year ahead came in steady for a third straight month at 3% in January.
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/02/43593480/wall-streets-most-accurate-analysts-give-their-take-on-3-real-estate-stocks-with-over-6-dividend-yields-2">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Real Estate Stocks With Over 6% Dividend Yields</a></li>
</ul>

Equities

Eurozone

Commodities

BDRX

MANH

MNDY

PLRX

SWTX

Crude Oil Rises Sharply; Manhattan Associates Shares Slide

U.S. stocks settled lower on Friday, with the Dow Jones index dipping more than 400 points as investors digested the jobs report for January. Wall Street also recorded losses last week as renewed fears over inflation and trade tariffs eroded risk appetite.
Wall Street analysts make new stock picks on a daily basis. Unfortunately for investors, not all analysts have particularly impressive track records at predicting market movements. Even when it comes to one single stock, analyst ratings and price targets can vary widely, leaving investors confused about which analyst&#8217;s opinion to trust.
Benzinga&#8217;s Analyst Ratings API is a collection of the highest-quality stock ratings curated by the Benzinga news desk via direct partnerships with major sell-side banks. Benzinga displays overnight ratings changes on a daily basis three hours prior to the U.S. equity market opening. Data specialists at investment dashboard provider Toggle.ai recently uncovered that the analyst insights Benzinga Pro subscribers and Benzinga readers regularly receive can successfully be used as trading indicators to outperform the stock market.
Top Analyst Picks: Fortunately, any Benzinga reader can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. One of the ways traders can sort through Benzinga&#8217;s extensive database of analyst ratings is by analyst accuracy. Here&#8217;s a look at the most recent stock picks from each of the five most accurate Wall Street analysts, according to Benzinga <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock</a> Ratings.
Analyst: Trevor Walsh
<ul>
<li>Analyst Firm: JMP Securities</li>
<li>Ratings Accuracy: 89%</li>
<li>Latest Rating: Maintained a Market Outperform rating on Cloudflare, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NET#NYSE">NET</a>) and raised the price target from $135 to $180 on Feb. 7. This analyst sees around 4% upside in the stock.</li>
<li>Recent News: On Feb. 6, Cloudflare reported quarterly earnings of 19 cents per share, which beat the analyst consensus estimate of 18 cents.</li>
</ul>
Analyst: Alexander Paris
<ul>
<li>Analyst Firm: Barrington Research</li>
<li>Ratings Accuracy: 88%</li>
<li>Latest Rating: Maintained an Outperform rating on H&amp;R Block, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HRB#NYSE">HRB</a>) with a price target of $70 on Feb. 5. This analyst sees a 32% surge in the stock.</li>
<li>Recent News: On Feb. 4, H&amp;R Block reported worse-than-expected second-quarter financial results.</li>
</ul>
Analyst: Mark Kelley 
<ul>
<li>Analyst Firm: Stifel</li>
<li>Ratings Accuracy: 86%</li>
<li>Latest Rating: Maintained a Buy rating on Amazon.com, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) and increased the price target from $245 to $275 on Feb. 7. This analyst sees around 18% upside in the stock.</li>
<li>Recent News: On Feb. 6, Amazon.com reported fourth-quarter net sales of $187.8 billion, up 10% year-over-year. The net sales beat a Street consensus estimate of $187.3 billion according to data from Benzinga Pro.</li>
</ul>
Analyst: Josh Sullivan
<ul>
<li>Analyst Firm: Benchmark</li>
<li>Ratings Accuracy: 86%</li>
<li>Latest Rating: Maintained a Buy rating on Planet Labs PBC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PL#NYSE">PL</a>) and raised the price target from $4 to $7 on Feb. 5. This analyst sees around 8% surge in the stock.</li>
<li>Recent News: On Jan. 28, the company's subsidiary Planet Labs Germany GmbH inked a multi-year agreement with the European Space Agency (ESA).</li>
</ul>
Analyst: John Todaro
<ul>
<li>Analyst Firm: Needham</li>
<li>Ratings Accuracy: 86%</li>
<li>Latest Rating: Maintained a Buy rating on Coinbase Global, Inc. &nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) and cut the price target from $420 to $330 on Feb. 7. This analyst sees around 18% upside in the stock.</li>
<li>Recent News: On Jan. 19, Coinbase announced the addition of Chris LaCivita, President Donald Trump&#8217;s co-campaign manager in 2024, to its Global Advisory Council.</li>
</ul>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/25/02/43593480/wall-streets-most-accurate-analysts-give-their-take-on-3-real-estate-stocks-with-over-6-dividend-yields-2">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Real Estate Stocks With Over 6% Dividend Yields</a></li>
</ul>

AMZN

COIN

This Analyst With 86% Accuracy Rate Sees More Than 18% Upside In Amazon.com, - Here Are 5 Stock Picks For Last Week From Wall Street's Most Accurate Analysts

Investors with a lot of money to spend have taken a bearish stance on Teva Pharmaceutical Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with TEVA, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 8 uncommon options trades for Teva Pharmaceutical Indus.
This isn't normal.
The overall sentiment of these big-money traders is split between 12% bullish and 50%, bearish.
Out of all of the special options we uncovered, 6 are puts, for a total amount of $288,604, and 2 are calls, for a total amount of $143,091.
<h3>Projected Price Targets</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $15.0 to $17.0 for Teva Pharmaceutical Indus during the past quarter. 
<h3>Insights into Volume &amp; Open Interest</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Teva Pharmaceutical Indus's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Teva Pharmaceutical Indus's whale trades within a strike price range from $15.0 to $17.0 in the last 30 days. 
<h3>Teva Pharmaceutical Indus 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739214939_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>TEVA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$3.15</td>
<td>$3.05</td>
<td>$3.05</td>
<td>$15.00</td>
<td>$91.2K</td>
<td>1.2K</td>
<td>301</td>
</tr>
<tr>
<td>TEVA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$2.16</td>
<td>$2.06</td>
<td>$2.16</td>
<td>$17.00</td>
<td>$76.8K</td>
<td>10.7K</td>
<td>611</td>
</tr>
<tr>
<td>TEVA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$1.28</td>
<td>$1.07</td>
<td>$1.28</td>
<td>$15.00</td>
<td>$74.2K</td>
<td>2.4K</td>
<td>592</td>
</tr>
<tr>
<td>TEVA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$0.52</td>
<td>$0.4</td>
<td>$0.51</td>
<td>$16.50</td>
<td>$51.8K</td>
<td>1.2K</td>
<td>1.0K</td>
</tr>
<tr>
<td>TEVA</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>06/20/25</td>
<td>$1.45</td>
<td>$1.38</td>
<td>$1.42</td>
<td>$17.00</td>
<td>$35.5K</td>
<td>15.3K</td>
<td>250</td>
</tr>
</tbody>
</table>

<h3>About Teva Pharmaceutical Indus</h3>
Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
In light of the recent options history for Teva Pharmaceutical Indus, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Where Is Teva Pharmaceutical Indus Standing Right Now?</h3>
<ul>
<li>With a volume of 4,482,422, the price of TEVA is down -0.68% at $16.71. </li>
<li>RSI indicators hint that the underlying stock may be oversold.</li>
<li>Next earnings are expected to be released in 86 days.</li>
</ul>
<h3>Expert Opinions on Teva Pharmaceutical Indus</h3>
In the last month, 4 experts released ratings on this stock with an average target price of $28.25.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from UBS continues to hold a Buy rating for Teva Pharmaceutical Indus, targeting a price of $27. 
&#x2A; An analyst from Piper Sandler persists with their Overweight rating on Teva Pharmaceutical Indus, maintaining a target price of $30. 
&#x2A; An analyst from Barclays persists with their Overweight rating on Teva Pharmaceutical Indus, maintaining a target price of $26. 
&#x2A; An analyst from UBS has decided to maintain their Buy rating on Teva Pharmaceutical Indus, which currently sits at a price target of $30. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Teva Pharmaceutical Indus options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

TEVA

Spotlight on Teva Pharmaceutical Indus: Analyzing the Surge in Options Activity

Financial giants have made a conspicuous bullish move on FTAI Aviation. Our analysis of options history for FTAI Aviation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTAI#NASDAQ">FTAI</a>) revealed 18 unusual trades.
Delving into the details, we found 61% of traders were bullish, while 38% showed bearish tendencies. Out of all the trades we spotted, 10 were puts, with a value of $406,128, and 8 were calls, valued at $3,388,990.
<h3>What's The Price Target?</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $85.0 to $130.0 for FTAI Aviation over the last 3 months. 
<h3>Insights into Volume &amp; Open Interest</h3>
In terms of liquidity and interest, the mean open interest for FTAI Aviation options trades today is 1262.7 with a total volume of 7,525.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for FTAI Aviation's big money trades within a strike price range of $85.0 to $130.0 over the last 30 days.
<h3>FTAI Aviation Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739214934_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>FTAI</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$34.6</td>
<td>$33.0</td>
<td>$33.1</td>
<td>$90.00</td>
<td>$3.1M</td>
<td>1.0K</td>
<td align="right">951</td>
</tr>
<tr>
<td>FTAI</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$14.5</td>
<td>$13.8</td>
<td>$13.8</td>
<td>$108.00</td>
<td>$56.5K</td>
<td>140</td>
<td align="right">100</td>
</tr>
<tr>
<td>FTAI</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$5.5</td>
<td>$5.4</td>
<td>$5.5</td>
<td>$100.00</td>
<td>$55.0K</td>
<td>179</td>
<td align="right">501</td>
</tr>
<tr>
<td>FTAI</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$6.0</td>
<td>$5.2</td>
<td>$5.5</td>
<td>$100.00</td>
<td>$55.0K</td>
<td>179</td>
<td align="right">301</td>
</tr>
<tr>
<td>FTAI</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$6.0</td>
<td>$5.2</td>
<td>$5.5</td>
<td>$100.00</td>
<td>$55.0K</td>
<td>179</td>
<td align="right">201</td>
</tr>
</tbody>
</table>

<h3>About FTAI Aviation</h3>
FTAI Aviation Ltd is a aerospace company .It owns and maintains commercial jet engines with a focus on CFM56 engines. FTAI owns and leases jet aircraft which often facilitates the acquisition of engines at attractive prices. It invests in aviation assets and aerospace products that generate strong and stable cash flows with the potential for earnings growth and asset appreciation.
Following our analysis of the options activities associated with FTAI Aviation, we pivot to a closer look at the company's own performance.
<h3>Where Is FTAI Aviation Standing Right Now?</h3>
<ul>
<li>With a trading volume of 1,047,297, the price of FTAI is up by 5.45%, reaching $118.99.</li>
<li>Current RSI values indicate that the stock is is currently neutral between overbought and oversold.</li>
<li>Next earnings report is scheduled for 16 days from now.</li>
</ul>
<h3>What Analysts Are Saying About FTAI Aviation</h3>
Over the past month, 2 industry analysts have shared their insights on this stock, proposing an average target price of $130.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Stifel persists with their Buy rating on FTAI Aviation, maintaining a target price of $100. 
&#x2A; An analyst from RBC Capital downgraded its action to Outperform with a price target of $160. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest FTAI Aviation options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

FTAI

FTAI Aviation Options Trading: A Deep Dive into Market Sentiment

Whales with a lot of money to spend have taken a noticeably bullish stance on SpringWorks Therapeutics.
Looking at options history for SpringWorks Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWTX#NASDAQ">SWTX</a>) we detected 68 trades.
If we consider the specifics of each trade, it is accurate to state that 42% of the investors opened trades with bullish expectations and 32% with bearish.
From the overall spotted trades, 3 are puts, for a total amount of $125,618 and 65, calls, for a total amount of $3,475,358.
<h3>Projected Price Targets</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $25.0 to $60.0 for SpringWorks Therapeutics over the recent three months. 
<h3>Volume &amp; Open Interest Trends</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for SpringWorks Therapeutics's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across SpringWorks Therapeutics's significant trades, within a strike price range of $25.0 to $60.0, over the past month.
<h3>SpringWorks Therapeutics 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739214929_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>SWTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>02/21/25</td>
<td>$12.8</td>
<td>$11.2</td>
<td>$12.0</td>
<td>$45.00</td>
<td>$270.0K</td>
<td>4.8K</td>
<td>2.0K</td>
</tr>
<tr>
<td>SWTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$21.0</td>
<td>$20.0</td>
<td>$21.0</td>
<td>$30.00</td>
<td>$203.7K</td>
<td>308</td>
<td>144</td>
</tr>
<tr>
<td>SWTX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$13.4</td>
<td>$12.5</td>
<td>$13.4</td>
<td>$40.00</td>
<td>$116.5K</td>
<td>3.9K</td>
<td>732</td>
</tr>
<tr>
<td>SWTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$27.1</td>
<td>$24.3</td>
<td>$26.0</td>
<td>$30.00</td>
<td>$104.0K</td>
<td>308</td>
<td>204</td>
</tr>
<tr>
<td>SWTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>02/21/25</td>
<td>$16.5</td>
<td>$14.7</td>
<td>$15.5</td>
<td>$40.00</td>
<td>$97.6K</td>
<td>3.9K</td>
<td>910</td>
</tr>
</tbody>
</table>

<h3>About SpringWorks Therapeutics</h3>
SpringWorks Therapeutics Inc is a clinical stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. The company has a differentiated portfolio of small molecule targeted oncology product candidates and is advancing two potentially registrational clinical trials in rare tumor types, as well as several other programs addressing highly prevalent, genetically defined cancers.
<h3>Where Is SpringWorks Therapeutics Standing Right Now?</h3>
<ul>
<li>Currently trading with a volume of 10,783,844, the SWTX's price is up by 37.09%, now at $55.22. </li>
<li>RSI readings suggest the stock is currently may be overbought.</li>
<li>Anticipated earnings release is in 10 days.</li>
</ul>
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for SpringWorks Therapeutics with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Smart Money Is Betting Big In SWTX Options

Vice President J.D. Vance is being put in charge of overseeing a deal to save TikTok after President Donald Trump changed his mind and decided to temporarily save the <a href="https://www.benzinga.com/general/social-media/25/01/43088960/trump-suspends-us-tiktok-ban-for-75-days-with-executive-order-but-legal-and-market-uncertainty-looms-over-platforms-future">Chinese social media app.</a>
What Happened: Vance, who is a <a href="https://www.benzinga.com/markets/cryptocurrency/24/07/39799850/5-things-you-might-not-know-about-j-d-vance-hillbilly-elegy-author-bitcoin-holder-first-mi">former venture capitalist</a>, is being tasked with helping land the best deal for the potential sale of TikTok's U.S. division to a buyer in the United States.
Vance and National Security Adviser Michael Waltz have been put in charge of the task, according to a Punchbowl <a href="https://punchbowl.news/article/tech/vance-waltz-tiktok-portfolio/">report</a>.
Sources say Vance is in charge of "quarterbacking a deal to save TikTok," which comes after Trump gave 75 days for TikTok parent ByteDance to work out a deal that would give the U.S. or an American company ownership of the U.S. TikTok division.
In 2024, Congress passed a bipartisan law banning TikTok, a decision later upheld by the U.S. Supreme Court. However, Trump's executive order delayed enforcement, leaving TikTok's future uncertain as ByteDance races to find a buyer and finalize a deal.
ByteDance temporarily shut off access to TikTok to hundreds of millions of Americans before reversing course after Trump's executive order. Smartphone owners in the U.S. who did not have TikTok previously installed are unable to download it during the current waiting period.
Vance and Waltz face challenges to make a deal that appeases several parties, including Trump, ByteDance, China, members of Congress, the Senate Intelligence Committee and the potential buying group.
As a former member of Congress and venture capitalist, Vance&#8217;s deal-making experience in both politics and investments could help broker an agreement. This move may also serve as an early test of his effectiveness in the vice-presidential role.
Trump previously suggested that the American government could own part of TikTok, potentially through the newly created U.S. sovereign wealth fund.
The president has voiced support for Oracle Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>) co-founder Larry Ellison or Tesla CEO Elon Musk <a href="https://www.benzinga.com/general/social-media/25/01/43181940/elon-musk-or-larry-ellison-dan-ives-on-who-could-win-tiktoks-billion-dollar-soap-opera-someone-hand-picked-from-beijing-but-also-trumps-white-house">buying TikTok. </a>Musk recently said he is not interested. Billionaire Frank McCourt, Shark Tank member Kevin O'Leary and content creator MrBeast are <a href="https://www.benzinga.com/25/01/43325891/backed-by-youtube-king-mrbeast-group-of-american-investors-including-roblox-ceo-lock-in-over-20-billion-for-tiktok-takeover-but-they-have-not-heard-back-directly-from-bytedance">among the names </a>that have expressed interest in buying TikTok.
Amazon.com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) and Microsoft Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) are also names that pop up with potential interest in acquiring a stake in TikTok, <a href="https://www.wsj.com/tech/trump-vance-tiktok-deal-0e3b8bc1">according </a>to The Wall Street Journal.
Did You Know?
<ul>
<li>Congress Is Making Huge Investments. <a href="http://•	https://www.benzinga.com/gov-trades/?utm_source=BZprocontent021025">Get Tips On What They Bought And Sold With Our Easy-to-Use Tool</a></li>
</ul>
<figure class="wp-block-image size-large"><a href="http://•	https://www.benzinga.com/gov-trades/?utm_source=BZprocontent021025"><img loading="lazy" decoding="async" width="1024" height="331" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/10140321/gov-trades2-1024x331.png" alt="" class="wp-image-775138" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/10140321/gov-trades2-1024x331.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/10140321/gov-trades2-300x97.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/10140321/gov-trades2-768x248.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/10140321/gov-trades2-1536x497.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/10140321/gov-trades2.png 1890w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Why It's Important: Vance's task of finding the right deal for all parties involved faces tough odds.
TikTok CEO Shou Chew met with White House officials last week and pitched a U.S. joint venture that would be headquartered in the United States with a board of directors made up of a majority of U.S. members, with the country also overseeing data security.
ByteDance has not been open to selling TikTok off in its entirety. The discussion of a TikTok deal also comes as Trump's tariff proposals and talks with China over trade could make the ByteDance-owned app a leverage piece in a potential trade war.
Vance was a former principal at Peter Thiel's Mithril Capital in 2016 and 2017. He later left Mithril to work at Revolution LLC in 2017, an investment firm founded by AOL founder Steve Case.
In 2019, Vance co-founded Narya Capital, a venture capital fund that received backing from Thiel, Eric Schmidt and Marc Andreessen.
With his venture capital history, Vance has experience in the technology sector and connections to several notable venture capitalists.
While Vance worked for several VC firms,<a href="https://www.benzinga.com/general/politics/24/07/39916075/j-d-vance-venture-capital-background-under-scrutiny-it-never-seemed-like-he-was-even-working-it-"> his work ethic</a> has been questioned by several former co-workers.
&#8220;It never seemed like he was even working,&#8221; a former coworker&nbsp;<a href="https://www.businessinsider.com/jd-vance-venture-capitalist-colleagues-2024-7" target="_blank" rel="noreferrer noopener">told&nbsp;</a>Business Insider. &#8220;It felt like his full-time job was the book.&#8221;
Former coworkers said Vance did not close a single deal a year after he started with the firm.
Vance has acknowledged his potential lack of contribution at Mithril.
&#8220;How useful I&#8217;ve been on that front is probably debatable,&#8221; Vance said in a previous interview on his venture capital history.
For Vance, securing a deal for TikTok could help win him praise from Trump and Congress members and silence the naysayers who doubt his VC deal-making abilities.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42654769/tiktok-ban-under-trump-president-elect-wants-to-keep-months-after-pelosi-said-follow-the-money">TikTok Ban Under Trump? President-Elect Reconsiders As Pelosi Says &#8216;Follow The Money&#8217;</a></li>
</ul>
Photo: Shutterstock

Politics

Global

MSFT

ORCL

JD Vance 'Quarterbacking' TikTok Deal: Will His Venture Capital Experience Secure A Win?

HIV-Treatment-focused giant&nbsp;Gilead Sciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) is scheduled to report fourth-quarter and full-year 2024 results on February 11, <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/b43286943/gilead-sciences-to-release-fourth-quarter-full-year-2024-financial-results-on-tuesday-february-11-" rel="noreferrer noopener">after the market close</a>.
Analysts estimate fourth-quarter adjusted EPS of $1.70 and revenues of $7.14 billion. The Wall Street forecasts fiscal year 2024 adjusted EPS of $4.41 and <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">sales of $28.31 billion</a>.
Gilead reported third-quarter adjusted EPS of $2.02, down from $2.29 a year ago, beating the consensus of $1.55.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/06/39435880/gilead-sciences-faces-wall-street-speculation-about-obesity-drugs-despite-focus-on-liver-treatmen" rel="noreferrer noopener">Gilead Sciences Faces Wall Street Speculation About Obesity Drugs Despite Focus On Liver Treatments</a>
The HIV drug maker reported third-quarter sales of $7.55 billion, up 7% year over year, beating the consensus of $7 billion, primarily due to higher sales in HIV and Veklury&nbsp;(remdesivir), Oncology, <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41819570/hiv-drugmaker-gilead-reports-strongest-quarterly-performance-of-2024-analysts-boost" rel="noreferrer noopener">and Liver Disease</a>.
Gilead will report the first full quarter sales from Livdelzi&nbsp;(seladelpar) after gaining FDA accelerated approval in mid-August 2024 for <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40394698/fda-approves-gileads-seladelpar-for-inflammatory-liver-disease-acquired-via-4b-cymabay-deal" rel="noreferrer noopener">primary biliary cholangitis</a>.
In October, Gilead Sciences&nbsp;announced plans to voluntarily withdraw the U.S. accelerated approval for Trodelvy (sacituzumab govitecan-hziy; SG) for adult patients with locally advanced or metastatic urothelial cancer who have previously received platinum-containing chemotherapy and either programmed death receptor-1 (PD-1) or programmed death-ligand <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41409405/after-failed-confirmatory-trial-gilead-withdraws-us-accelerated-approval-of-trodelvy-as-bladder-c" rel="noreferrer noopener">1 (PD-L1) inhibitor</a>.
In January, Gilead Sciences&nbsp;and&nbsp;LEO Pharma&nbsp;announced a strategic partnership to accelerate the development and commercialization of LEO Pharma&#8217;s small molecule oral STAT6 for inflammatory diseases.
Gilead will acquire LEO Pharma&#8217;s comprehensive preclinical oral STAT6 small molecule inhibitors and targeted protein degraders.
Gilead will lead further development efforts for the oral programs, while LEO Pharma will lead the development of potential topical formulations of STAT6 inhibitors.
LEO Pharma can receive up to $1.7 billion, including an upfront payment of $250 million.
In addition, LEO Pharma may also receive tiered royalties ranging from the high single-digits to the mid-teens on sales of oral STAT6 products.
The transaction with LEO Pharma is expected to reduce Gilead&#8217;s GAAP and non-GAAP 2025 EPS by <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/b42932896/gilead-and-leo-pharma-enter-into-strategic-partnership-to-accelerate-development-of-oral-stat6-pro" rel="noreferrer noopener">approximately $0.15 &#8211; $0.17</a>.
Price Action: GILD stock is down 0.78% at $95.29&nbsp;at last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43597062/incyte-records-15-jump-in-2024-sales-on-strong-jakafi-opzelura-sales-says-2025-to-be-catalyst-rich-including-four-launches" target="_blank" rel="noreferrer noopener">Incyte Q4 Earnings: EPS Miss, Strong Jakafi And Opzelura Sales, Says 2025 To Be Catalyst Rich Including 4 Launches</a></li>
</ul>
Photo via Shutterstock

Biotech

Earnings

Large Cap

Guidance

General

GILD

What To Expect When Biotech Giant Gilead Reports Q4 Earnings On Tuesday?

Marvell, Nvidia lead AI semiconductor picks in 2025: Barclays

Companies in the Technology sector have received a lot of coverage today as analysts weigh in on Credo Technology Group Holding Ltd (CRDO – Researc...

Analysts Offer Insights on Technology Companies: Credo Technology Group Holding Ltd (CRDO), Agilysys (AGYS) and Seagate Tech (STX)

Credo: Risky Consumer Concentration And Expensive Valuations, Minimal Margin Of Safety

Credo Technology: Don't Believe Its Valuation

Semiconductor stocks stumble as DeepSeek shocks the market; See 10 semi names to watch

Credo Technology: This Top SA Quant Pick Is Now 30% Cheaper

Credo Technology Group: One Of My Top Inflection Stocks, Path To $105

Credo Technology May Actually Be Very Cheap Today

Credo Technology: A 'Meh' Product In A 'Wow' Market

Credo Technology's Hyperscaler Boom: Could This Be AI's Next High Growth Winner

AGYS

FTXL

GOOG

INTC

LITE

QCOM

SEMI

SOXL

SOXX

TSMWF

Press Releases

Credo to Showcase Datacenter AI, Compute and CXL with XConn PCIe and CXL Switches at OCP Global Summit 2024

Credo Announces PCI Express 6 /7, Compute Express Link CXL 3.x Retimers, and AEC PCI Express Product Line at OCP Summit 2024

Credo and Net One Systems Join Forces to Bring Active Electrical Cables to the Japanese Market

Credo Schedules Second Quarter Fiscal Year 2025 Financial Results Conference Call

Credo Completes First GHG Emissions Calculation, Strengthens Commitment to Environmental Sustainability

Credo Releases 2024 Environmental, Social, and Governance (ESG) Report

Credo to Present at Barclays 22nd Annual Global Technology Conference

Credo Reports Second Quarter of Fiscal Year 2025 Financial Results

Demand For Helium is Becoming an Extremely High-Value Commodity and Billion Dollar Industry

Credo to Exhibit at Chiplet Summit 2025

NEHC

NEHCW

PSRHF

ROCL

TSXV:PLSR

Analog Devices

Astera Labs

Advanced Micro Devices, Inc. - Common Stock

Advanced Micro Devices

Arm Holdings plc - American Depositary Shares

ARM Holdings

ASE Technology Holding Co., Ltd. American Depositary Shares (each representing Two Common Shares)

Comments

Credo Technology Group

Noticias

Últimas noticias sobre Credo Technology Group (NASDAQ:CRDO) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL